Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6614940 | 0.79 | HDAC8 (0.38) | GSK3AGSK3BMGLLDHFRSIGMAR1 | |
| SCHEMBL9201461 | 0.76 | SIGMAR1 (0.46) | GSK3AGSK3BMGLLSIGMAR1F2 | |
| SCHEMBL24938710 | 0.74 | MGLL (0.45) | GSK3AGSK3BMGLLSIGMAR1F2 | |
| Hydrochloric Acid SCHEMBL28835985 | 0.72 | MGLL (0.43) | GSK3AGSK3BMGLLSIGMAR1F2 | |
| SCHEMBL24609402 | 0.71 | CYP11B1 (0.40) | GSK3AGSK3BMGLLSIGMAR1HTR2A | |
| Hydrochloric Acid SCHEMBL30234811 | 0.71 | MGLL (0.42) | GSK3AGSK3BMGLLSIGMAR1F2 | |
| SCHEMBL14437018 | 0.71 | MGLL (0.42) | GSK3AGSK3BMGLLSIGMAR1F2 | |
| SCHEMBL21104726 | 0.69 | SIGMAR1 (0.43) | GSK3AGSK3BMGLLSIGMAR1F2 | |
| SCHEMBL8672368 | 0.67 | SIGMAR1 (0.41) | GSK3AGSK3BMGLLSIGMAR1F2 | |
| SCHEMBL11258019 | 0.66 | SRC (0.47) | GSK3AGSK3BMGLLSIGMAR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019385-B1 | AMINOARYL OXAZOLIDINONE N-OXIDES | UPJOHN CO (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6525193-B2 | Bactericides | PHARMACIA & UPJOHN COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6518427-B1 | Compounds are exceedingly water soluble which is useful in preparing pharmaceutical formulations of these compounds. They are also rapidly converted back to the parent amines in vivo, making them useful as prodrugs of the parent amines. | PHARMACIA & UPJOHN COMPANY | 2003-02-11 | — | — | US | disclosed |
| US-6515135-B2 | Exceedingly water soluble; rapidly converted back to the parent amines in vivo, making them useful as prodrugs of the parent amines. | PHARMACIA & UPJOHN COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6512112-B2 | Useful as prodrugs, easily convert to parent amine in vivo; antibiotic activity versus gram negative aerobic and anaerobic bacteria | PHARMACIA & UPJOHN COMPANY | 2003-01-28 | — | — | US | disclosed |
| US-20020177707-A1 | AMINOARYL OXAZOLIDINONE N-OXIDES | GADWOOD ROBERT C (US) | 2002-11-28 | — | — | US | disclosed |
| US-20020120152-A1 | Aminoaryl oxazolidinone N-oxides | GADWOOD ROBERT C (US) | 2002-08-29 | — | — | US | disclosed |
| US-6441188-B1 | SUCH AS (S)-N-((3-(3-FLUORO-4-(1,1-DIOXOTHIAZOLIDIN-3-YL) PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)ACETAMIDE N-OXIDE FOR TREATMENT OF MICROBIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020107402-A1 | Aminoaryl oxazolidinone N-oxides | GADWOOD ROBERT C (US) | 2002-08-08 | — | — | US | disclosed |
| US-20010051722-A1 | Useful as prodrugs, easily convert to parent amine in vivo; antibiotic activity versus gram negative aerobic and anaerobic bacteria | GADWOOD ROBERT C (US) | 2001-12-13 | — | — | US | disclosed |
| US-6277985-B1 | AS ANTIBIOTICS; WATER SOLUBILITY; IN PRODRUGS | PHARMACIA & UPJOHN COMPANY | 2001-08-21 | — | — | US | disclosed |
| EP-1019385-A1 | AMINOARYL OXAZOLIDINONE N-OXIDES | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1997010223-A1 | AMINOARYL OXAZOLIDINONE N-OXIDES | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051722-A1 | Useful as prodrugs, easily convert to parent amine in vivo; antibiotic activity versus gram negative aerobic and anaerobic bacteria | AMD1, CYP11B1, ALDH7A1 | GSK3A 2498/4885GSK3B 2377/4885MGLL 1960/4885 |
| US-20020107402-A1 | Aminoaryl oxazolidinone N-oxides | CYP11B1, ABAT, MSMO1 | GSK3A 1298/4885GSK3B 1225/4885MGLL 1904/4885 |
| US-20020120152-A1 | Aminoaryl oxazolidinone N-oxides | CYP11B1, ABAT, MSMO1 | GSK3A 1298/4885GSK3B 1225/4885MGLL 1904/4885 |
| US-20020177707-A1 | AMINOARYL OXAZOLIDINONE N-OXIDES | CYP11B1, ABAT, MSMO1 | GSK3A 1298/4885GSK3B 1225/4885MGLL 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.